Condition: Multiple Myeloma · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma (MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy
This description comes directly from the study's public registry record.
Lugui Qiu · 0086-022-23909171 · qiulg@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06158269